AVP and chronic kidney disease: In a randomised trial of coached water intake in CKD stage 3 assessing a primary outcome of eGFR change over 12 months, for an average 0.7-L increase in water intake for the intervention group, copeptin decreased, but no significant eGFR change was seen [99].